Victorian Cancer Biobank (VCB) (Australia) | B.R.I.D.G.E. TO DATA®, DGI, LLC

Summary

Coordinating Country

Australia

Region

Victoria

[The Victorian Cancer Biobank (VCB) is a consortia of hospital sites across the Melbourne metropolitan region including:
- Austin Health,
- Eastern Health,
- Melbourne Health,
- Monash Health,
- Peter MacCallum Cancer Centre, and
- Cancer Council Victoria (lead agency).

The VCB network consists of five tissue bank sites and four repositories across a network of 26 hospitals within Victoria. Central Operations is based at the Cancer Council Victoria.]

Brief Database Description

The Victorian Cancer Biobank (VCB) is operated by a consortium that collects and distributes tissue samples to support cancer research in Victoria, Australia and throughout the world with the aim of delivering better clinical outcomes to people with cancer.

Since operations commenced in 2006, more than 39,000 Victorians undergoing cancer and other surgery have donated blood and surplus tissue to the Biobank. Applications have been received from >350 cancer research groups located within Australia and overseas, and >50,000 biospecimens prepared from donated blood and tissues have been supplied with de-identified medical information.

VCB has an extensive collection of human biospecimens of various tumor types, annotated with clinical data such as cancer history, treatment history, lifestyle factors, and survival data. VCB provides a complimentary de-identified pathology report along with the biospecimens shipped.

VCB obtains consent to collect blood and tissue samples from healthy donors and patients diagnosed with cancer. Operating as a hub-and-spokes collection model with a centralized database across Victoria, VCB’s success is due to its collaboration with local pathologists, medical oncologists, surgeons, and other hospital personnel. Five academic teaching hospitals across Melbourne currently house their main tissue banks; the main tissue banks also collaborate with multiple satellite sites to collect critical masses of specimens for research projects. Specially trained tissue bank staff obtain patient consents, collect, process and store tissue and blood samples.

Clinical pathologists select fresh tissue for research as matched pairs (tumor and adjacent normal) within an hour of surgical resection. The majority of solid tissue samples have a corresponding blood sample taken pre-operatively. Blood samples are also processed and stored within two hours of collection.

VCB is now one of the largest multi-center collection facilities of its kind in the world, collecting tissue and blood from donors at 26 public and private hospitals in metropolitan Melbourne. VCB has an open-door policy to public and private investigators or companies that have an ethically approved research project. VCB is customer-focused with an enviable archival collection of >460,000 biospecimens in various storage formats and can support prospective collections.

VCB collects various types of clinical data over the course of a patient’s disease for up to a five-year period. Data provided to researchers are encrypted with a unique code to ensure patient privacy and confidentiality. Additional clinical data can be collected subject to project ethics approval and availability.

1. De-identified Histopathology Report include:
- Age
- Sex
- Clinical Diagnosis
- Tissue Pathology
- Grade/Stage (if available)

2. Lifestyle Factors:
- Smoking status
- Alcohol consumption

3. Comorbidities

4. Diagnostic Biomarkers

5. Diagnostic Mutation Status

6. Cancer History:
- Personal history of cancer
- Family history of cancer

7. Survival data: 5-10 years

8. Treatment details and history:
-Pre-operative
-Post-operative

VCB is a not-for-profit biobank funded by the Victorian Government’s Department of Health and Human Services with the Cancer Council Victoria as lead agency. The funding goals are to provide high quality, ethically obtained biospecimens to support research that will eventually lead to improvements in cancer diagnosis and treatment. The VCB is a consortia of hospital sites across the Melbourne metropolitan region including: Austin Health, Eastern Health, Melbourne Health, Monash Health and Peter MacCallum Cancer Centre. The VCB network consists of five tissue bank sites and four repositories across a network of 27 hospitals within Victoria.

Database Type

Tissue/Blood and Genomic/Pharmacogenetic Database

- Biobank

- - Disease-based

[VCB contains tissue specimens (archival, prospective) and clinical data. Victorians undergoing cancer and other surgery have donated blood and surplus tissue to VCB.]

Database Source

Medical Records

Victorian Cancer Registry linkage
Patient Questionnaires
(Biospecimens)

Frequency of Data Collection

Ongoing

Frequency of Data Update

Ongoing

Years Covered

1999 - Present

Population Type

Inpatient

[VCB is a collection of blood and tissue samples taken from healthy individuals or patients diagnosed with cancer or at risk of developing cancer. Clinical pathologists select fresh tissue for research as matched pairs (tumor and adjacent normal) within an hour of surgical resection. The majority of solid tissue samples have a corresponding blood sample taken pre-operatively. Blood samples are also processed and stored within two hours of collection.]

Patient Type

Inpatient

Date of Last Update

Ongoing

The Victorian Cancer Biobank is updated on an ongoing basis.
This profile was updated for the B.R.I.D.G.E. TO DATA site on March 19, 2024.

Population Dynamics

Database Population Size

<200,000

(Since operations commenced in 2006, more than 39,000 Victorians undergoing cancer and other surgery have donated blood and surplus tissue to the Biobank. Applications have been received from >350 cancer research groups located within Australia and overseas, and >50,000 biospecimens prepared from donated blood and tissues have been supplied with de-identified medical information.)

Active Population Size

<200,000

Annual Change in Population

N/A

(Not applicable)

Sample Weights - Extrapolation Factors

Final Population Size

N/A

(Not applicable as data are still being collected)

Demographic Data

Age of Patients at Data Collection

Yes

DOB is recorded, but not provided to researchers. Only the age of patient is provided in the de-identified histopathology report for researchers.

Approximate Percentage of Participants <18 years and those >65 years

< 18 years = 38
> 65 years = 13,075

Gender Data

Yes

Gender of patient is provided in the de-identified histopathology report for researchers.

Percentage of Males/Females

Males = 15,249
Females = 21,422

Ethnicity / Race Data

Yes

(If provided by the patient)

Geographic Location

Yes

There is a suburb data field in the VCB database, but this is not disclosed to researchers

Date of Birth Recorded

Yes

DOB is recorded, but not provided to researchers. Only the age of patient is provided in the de-identified histopathology report for researchers.

Death Recorded

Yes

VCB collects three categories of clinical data over the course of a patient’s disease for up to a five-year period. Data provided to researchers are encrypted with a unique code to ensure patient privacy and confidentiality. Date of death is recorded but is not disclosed to researchers; generally the age of death is provided to researchers.

Availability of death certificate / autopsy information

Other Demographic Data

Physician & Practioner Info

Physician ID

Physician Specialty

Pharmacy ID

N/A

(Not applicable)

Diagnoses/Signs & Symptoms

Diagnosis Data

Yes

Diagnosis data include:
- Histopathological diagnosis
- Previous history of cancer

Diagnoses Coded

ICD-O-3

Diagnoses: Date Parameters

1999 - Present

Diagnoses: Maximum Number of Codes Allowed

Generally 1 diagnosis is recorded per specimen collection unless the patient has multiple diagnoses

Physical Examination Findings

However, height and weight can be collected upon request

Birth Defect Data

Cancer Data

Yes

Cancer data include:
- Cancer Diagnosis
- Tissue Pathology
- Grade/Stage
- Diagnostic biomarkers
- Diagnostic mutation status
- Personal history of cancer
- Family history of cancer
- Survival data 5-10 years
- Cancer treatment history

Infectious Disease Data

Yes

Data are recorded on infectious diseases such as HIV, Tuberculosis, Hepatitis B, Hepatitis C, and COVID-19 status (January 23, 2020 onwards).

Environmental Exposures

Behavioral Data Elements

Yes

Information on smoking status and alcohol consumption is captured

Procedures

Procedure Data

Yes

(If procedures are part of the cancer treatment history)

Procedures Coded

Number of Procedures Coded

One procedure is recorded in the procedure field. If there are additional procedures, this can be recorded in another field.

Procedure Date Parameters

1999 - Present

Laboratory Information

Yes

Laboratory information may include diagnostic biomarkers, diagnostic mutation status of tumors, and other diagnostic testing that may be a part of the patient's clinical history.
Additional tests data can be provided if available.

Drug Information

Drug Data

Yes

Medication data are not part of the standard dataset and are only collected upon client request; however, information on medications and treatment drugs can be provided.

Drug Date Parameters

N/A

(Not applicable; medications are not part of the standard dataset and are only collected upon client request.)

Drug Regimen & Route

Yes

Cancer drug regimen information is collected

Drug Manufacturer

Drug Dosage

Yes

- Hormone therapy drug in mg
- Radiotherapy dose in Gy

Drug Days Supply

Drug Coding System: Maximum Number

Unlimited

Drug Coding System: Primary

N/A

(Not applicable)

Drug Coding System: Other

N/A

(Not applicable)

Drug Generic Name

Yes

Generic drug names are generally included, but not always

Drug Additional Information

Biobanks

Biobank Type

Disease-based

Human Specimen

Archival collections:
- Tumor tissue (Formalin-fixed paraffin embedded block, Snap Frozen, Optical coherence tomography block)
- Normal adjacent tissue (Formalin-fixed paraffin embedded block, Snap Frozen, Optical coherence tomography block)
- Blood (Plasma, Serum, Buffy coat, Peripheral blood mononuclear cells)
- Bone Marrow (mononuclear cells)

Prospective collections (Specimen types indicated in archival collections as well as the following can be collected):
- Fresh tissue
- Tissue biopsy
- Whole blood
- Whole bone marrow
- Pleural fluid
- Urine

Blood Type

Blood Type is not part of the VCB standard dataset; however it can be provided if available for selected cases

Biomarkers

Yes

Although VCB consortium was formed in 2006, VCB has been banking samples of suitable quality for biomarker studies since 2000. VCB has future proofed thousands of samples by storing mirror collections at both -80°C and liquid nitrogen temperatures, which are routinely called for in biomarker studies.

Key Biomarker Services include collection and storage of a variety of samples:
- Blood and tissue samples processed and stored within under 2 hours of collection; and
- Pre-operative biochemistry results.

To enquire about the current availability of specimens or to tailor a collection to your specific requirements, please contact VCB directly.

Patient ID

Patient ID number

All specimens have a unique identifer that is linked to the patient ID number in the database.

All biospecimens and associated clinical data are de-identified so that a patient’s identity is accessible only to VCB authorized staff. When materials or information are released to researchers they are labeled with a unique number only. Researchers will not be able to find out who the donor is, unless the donor specifically allows the disclosure of their personal information to particular researchers. Identifying information is not disclosed to any recipient medical researchers.

Number of Samples

Yes

For VCB archival collections, each patient generally has the following number of blood specimens:
- 8x 250µl serum,
- 8x 250µl plasma,
- 4x pellet buffy coat, and
- 4x PBMNCs;
They may also have matched tissue specimens:
- Tumour + Adjacent Normal snap frozen tissue, and
- Tumour + Adjacent Normal FFPE block

Frequency of Sample Collection

Varies

[Most archival collections are from one timepoint. Some of the cases have sample collections from multiple timepoints (e.g., pre-operative blood, post-operative blood, follow-up blood, or primary versus metastasis collections).

For prospective collections, the number of collection timepoints depends on the project requirements.]

Pre-diagnostic Sample Collection

Yes

Clinical pathologists select fresh tissue for research within an hour of surgical resection, and blood samples are taken pre-operatively

Post-treatment Sample Collection

Yes

Some biospecimens in VCB are from cancer patients that have undergone treatment

Method of Sample Collection

VCB is a collection of blood and tissue samples taken from healthy individuals or patients diagnosed with cancer or at risk of developing cancer.

Age at Sample Collection

Yes: As part of the clinical annotation

Date of Sample Collection

Yes

(DD-MM-YYYY)

Reason for Sample Collection

Clinical trial
Diagnostic
Genetic testing
Biomedical / Laboratory research

VCB supports cancer and non-cancer projects that involve one or more of the following research categories:
Biomarker discovery
Cancer related biology
Clinical trial
Diagnostic development
Genomic research
Proteomic research
Translational research

Method of Sample Storage

VCB has practices and procedures to ensure excellent quality specimens, including the following collection and storage practices:

- Formalin-fixed paraffin embedded blocks: Room temperature;
- Snap frozen tissue and Peripheral blood mononuclear cells: Liquid nitrogen vapor phase;
- Optical coherence tomography block, Plasma, Serum, and Blood pellet: -80°C;
- Tissues are frozen within 60 minutes of collection;
- Blood is processed and stored within 2 hours of collection;
- All formalin-fixed paraffin-embedded and occult coherence tomography cases are verified by a pathologist;
- All samples are labeled with a unique Tissue Bank Number;
- Storage equipment is checked and monitored daily.

Length of Sample Storage

Indefinite

Pathology

Samples of normal and disease

VCB collects the following from each tissue donor:
- Fresh normal and cancer tissue;
- Permission to use tissue stored in paraffin wax blocks;
- A blood sample; and
- Information about his/her health relevant to cancer.

DNA Isolation

Yes

DNA and RNA extractions are performed as requested. VCB is able to support both small and high volume request with a partly automated process. Spectrophotometric measurements are performed on every extraction.
Each batch of DNA is quality tested to evaluate purity (absorbance). VCB strives to provide DNA free of RNA, protein, organic compound and salt contamination. As per VCB standards and international best practices, the A260/A280 of extracted DNA must be between 1.7 and 1.9.

RNA Isolation

Yes

Cell Culture

Yes

Researchers can request cell culturing services by VCB

Genetic Testing

Yes

Customized tissue microarrays are made to order using VCB paraffin blocks or the researcher's blocks. VCB tissue microarrays are mapped outlining the contents and de-identified data reports for each block core used in the preparation of the tissue microarray.

Access for Research: Specimens

Yes, for clinical and/or epidemiologic research

The aim of the Biobank is to build up a large collection of cancer specimens linked to medical information about individuals with cancer, that can be used for future research.

Researchers from within Australia, or even overseas, can apply to VCB for biospecimens and information to use in a cancer research project. Before it is provided, it must be approved by the VCB Access Committee.

Access for Research: Genetic Data

Yes

Access for Research: Epidemiologic Data

N/A

(Not applicable)

Quality Assurance Procedures

Yes

VCB’s Quality Management System has been developed to comply with NCI and ISBER best practices for repositories. Tissue is selected and histologically examined by pathologists to determine the percentage of tumor and to confirm the banked sample matches the primary diagnostic material.

Qualified Biobank staff are trained to prepare samples using standardized protocols at all sites. Regular auditing and quality checks ensure procedural compliance and guarantee uniform high quality samples.

All specimens are stored in temperature monitored facilities.

Family History

Yes

Medical History

Yes

VCB also asks the donor questions, and gathers information from the donor's health records relevant to their cancer that may be useful in research. This information may be obtained from pathology reports, medical records or cancer registries and will include the donor's treatment and progress over time.

Biobank Linkage

Yes

(Survival data and diagnosis can be linked to the Victorian Cancer Registry database)

Genetic-PGx Data

Type of Genetic Database

N/A

Source of Genetic Data

N/A

Specimen Genotyped

N/A

Tissue Form

N/A

Genetic Template

N/A

Gene-Drug Response

N/A

Gene-Disease Relationship

N/A

Gene-Health Outcome Relationship

N/A

Gene-Environment Response

N/A

Method of Imputing Genetic Data

N/A

Genetic Variant Identification

N/A

Genetic Data Level

N/A

Genotyping Method

N/A

Method of Genetic Variant Filtering

N/A

Haplotypes

N/A

Haplogroups

N/A

Variable Number of Tandem Repeats (VNTR)

N/A

Single Nucleotide Polymorphisms (SNPs)

N/A

Variant Type

N/A

Variant Class

N/A

Mutation Indicated

N/A

Position

N/A

Amino Acid Change

N/A

Genotype / Polymorphism

N/A

Allele Frequency

N/A

Linkage Disequilibrium (r²)

N/A

Noncarriers Indicated

N/A

Association Statistics

N/A

Genetic Relatedness Pairing

N/A

Data Sharing: Genetic Data

N/A

Access for Research

N/A

Genetic Data Linkage

N/A

Description of Genetic Data Linkage

N/A

Economic Data

Cost Data

Cost Denomination

N/A

(Not applicable)

Type of Cost Data

N/A

(Not applicable)

Surrogate Cost Data Link

N/A

(Not applicable)

Description of Surrogate Link

N/A

(Not applicable)

Validation & Linkage

Data Validation Against Original Source

Yes

Tissue is selected and histologically examined by pathologists to determine the percentage of tumor, as well as to confirm that the banked sample matches the primary diagnostic material. Clinical follow up and outcome information is collected for up to 10 years.

Dedicated specially-trained personnel at each biobank extract comprehensive clinical data from patients and medical records and enter it into a central-database. VCB can provide detailed, non-identifying information to researchers on ~300 clinical data elements. Data audits are conducted annually to verify compliance and test for data errors. The database platform used by the VCB is OpenSpecimen™, a Krishagni product.

The preservation of materials for research is a careful science. Every step from resection to storage can diminish the usefulness of the specimen for research purposes. VCB has practices and procedures to ensure excellent quality specimens, including the following collection and storage practices:
- Tissues are frozen within 60 minutes of collection;
- Blood is processed and stored within 2 hours of collection;
- Mirror collections of tissue and blood specimens are stored in -80°C and the vapor phase of liquid nitrogen;
- All formalin-fixed paraffin-embedded and optical coherence tomography cases are verified by a pathologist;
- All formalin-fixed paraffin-embedded and optical coherence tomography sectioned cases come with a complimentary H&E slide verification;
- All samples are labeled with a unique Tissue Bank Number; and
- Storage equipment is checked and monitored daily.

Operations are standardized to international best practices, with audit systems in place to ensure compliance and regular testing to assure quality. Dedicated staff control the process, from obtaining consent to collection, storage and data management. This enables VCB to bank consistently high-quality samples and clinical data while protecting patient-donor safety and privacy. Stringent quality control over samples and data is continuously enforced. Moreover, personnel at the collection centers are trained quarterly on technical updates. VCB will be obtaining ISO certification in the near future. This means that VCB will meet international standards, not just best practice for high-quality collection, storage and release of human biospecimens.

Standard operating procedures (SOPs) have been developed in consultation with pathologists, scientists, consumer groups and ethicists to ensure practical, high quality, standardized sample and data collection and processing across all collection centers and protection of patient-donor safety and privacy. VCB has developed and implemented protocols covering:
- Tissue sample processing and archiving;
- Patient data collection and patient identification protection;
- Equipment maintenance; and
- Sample distribution to qualified researchers.
These protocols are designed to maximize the molecular and histological integrity and quality of the samples.

VCB staff members are qualified medical scientists with formal training in biomedical and/or clinical research, nursing and pathology. Personnel at all of biobank sites, including the staff at VCB Central Operations are trained and tested on all SOPs annually to ensure compliance and encourage professional development.

Access to Medical Records

Yes

Linkage to Other Databases

Yes

Brief Description of Linkage Capabilities

Survival data and diagnosis can be linked to the Victorian Cancer Registry database.

Administrative Information

Database Contact Data

Wayne Ng, PhD
General Manager
Victorian Cancer Biobank
615 St. Kilda Rd
Melbourne, Victoria 3004
AUSTRALIA
Phone: +61 3 9514 6179
Email: Wayne.Ng@cancervic.org.au

Website

https://viccancerbiobank.org.au/

Alternate Contact

1. Enquiries
Project Manager
Victorian Cancer Biobank
615 St Kilda Rd
Melbourne, Victoria 3004
AUSTRALIA
Phone: +61 3 9514 6186
Email: VCBEnquiries@cancervic.org.au

2. If you cannot reach the database manager, you may contact the Biobank by completing the contact form at: https://viccancerbiobank.org.au/services/enquire

Source of Database Funding

Government

(VCB is a not-for-profit biobank funded by the Victorian Government’s Department of Health and Human Services with the Cancer Council Victoria as lead agency. The funding goals are to provide high quality, ethically obtained biospecimens to support research that will eventually lead to improvements in cancer diagnosis and treatment. VCB is a consortia of hospital sites across the Melbourne metropolitan region including; Austin Health, Eastern Health, Melbourne Health, Monash Health and Peter MacCallum Cancer Centre. The VCB network consists of five tissue bank sites and four repositories across a network of twenty six hospitals within Victoria.)

Sponsoring Government Agency

VCB, through the Cancer Council Victoria as Lead Agency, is supported by the Victorian Government through the Victorian Cancer Agency, a business unit of the Department of Health and Human Services.

Sponsoring Pharmaceutical Manufacturer

N/A

(Not applicable)

Database Usage Restrictions

Private Access

(Open Access to any researchers with an ethically approved project)

Charge for Database Usage

Yes

An online specimen catalogue is available on the VCB website and allows potential applicants to search for available tissue and blood specimens:
https://viccancerbiobank.org.au/for-researchers/specimen-catalogue/

VCB's centralized application and dispatch process enables researchers to communicate directly with the Project Manager. It is recommended that researchers view the step-by-step instructions and download the information provided on the website before proceeding:
https://viccancerbiobank.org.au/for-researchers/applying-for-biospecimens/

A quote can be provided upon request.

Data Media Format

PDF Files

Excel / CSV

Number of Publications Using Database

>10

Please contact database manager for more recent publications.

References of Studies Using/Describing Database

1. Joyce R, Pascual R, Heitink L, Capaldo BD, Vaillant F, Christie M, Tsai M, Surgenor E, Anttila CJ, Rajasekhar P, Jackling FC. Identification of aberrant luminal progenitors and mTORC1 as a potential breast cancer prevention target in BRCA2 mutation carriers. Nature Cell Biology. 2024 Jan 12:1-5.

2. Li R, Liu S, Yeo K, Edwards S, Li MY, Santos R, Kianpour Rad S, Wu F, Maddern G, Young J, Tomita Y. Circulating SFRP5 levels are elevated in colorectal cancer and correlate with overall survival in stage II-III disease. medRxiv. 2024:2024-03.

3. Tan T, Mouradov D, Lee M, Gard G, Hirokawa Y, Li S, Lin C, Li F, Luo H, Wu K, Palmieri M. Unified framework for patient-derived, tumor-organoid-based predictive testing of standard-of-care therapies in metastatic colorectal cancer. Cell Reports Medicine. 2023 Dec 19;4(12).

4. Lam GT, Sorvina A, Martini C, Prabhakaran S, Ung BS, Lazniewska J, Moore CR, Beck AR, Hopkins AM, Johnson IR, Caruso MC. Altered endosomal-lysosomal biogenesis in melanoma. Neoplasia. 2023 Sep 1;43:100924.

5. Weeden CE, Gayevskiy V, Marceaux C, Batey D, Tan T, Yokote K, Ribera NT, Clatch A, Christo S, Teh CE, Mitchell AJ. Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. Cancer Cell. 2023 May 8;41(5):837-52.

6. Leong TL, Aloe C, Aujla S, Wang H, Gayevskiy V, Asselin-Labat ML, Gray LA, Steinfort D, Bozinovski S. Heterogeneity of tumour mutational burden in metastatic NSCLC demonstrated by endobronchial ultrasound sampling. Frontiers in Oncology. 2023 Mar 13;13:1150349.

7. Cain SA, Pope B, Mangiola S, Mantamadiotis T, Drummond KJ. Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression. BMC cancer. 2023 Mar 7;23(1):216.

8. Coombes C, Horikawa K, Jain S, Jiang S, Lim JH, Saxena K, Shadbolt B, Smyth L, Tobin J, Talaulikar D. Diffuse large B-cell lymphoma and red cell autoimmunity: clinical role and pathogenesis. Pathology. 2023 Feb 1;55(1):104-12.

9. Shewell LK, Day CJ, Hippolite T, De Bisscop X, Paton JC, Paton AW, Jennings MP. Serum Neu5Gc biomarkers are elevated in primary cutaneous melanoma. Biochem Biophys Res Commun. 2023 Jan 29;642:162-166.

10. Boys, Emma, Jia Liu, Zhaoxiang Cai, Zainab Noor, Karen L. Mackenzie, Adel Aref, Erin Sykes et al. Pan-cancer diagnostic proteomic signature of tissue-of-origin (TOO) using data-independent acquisition mass spectrometry (DIA-MS) from 1289 human tissue samples. Journal of Clinical Oncology. 2023;41(16): 3120-3120.

Database Contact

Database Contact Data

Wayne Ng, PhD
General Manager
Victorian Cancer Biobank
615 St. Kilda Rd
Melbourne, Victoria 3004
AUSTRALIA
Phone: +61 3 9514 6179
Email: Wayne.Ng@cancervic.org.au

Alternate Contact

1. Enquiries
Project Manager
Victorian Cancer Biobank
615 St Kilda Rd
Melbourne, Victoria 3004
AUSTRALIA
Phone: +61 3 9514 6186
Email: VCBEnquiries@cancervic.org.au

2. If you cannot reach the database manager, you may contact the Biobank by completing the contact form at: https://viccancerbiobank.org.au/services/enquire

Literature References

References of Studies Using/Describing Database

7. Cain SA, Pope B, Mangiola S, Mantamadiotis T, Drummond KJ. Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression. BMC cancer. 2023 Mar 7;23(1):216.